NNZ-2566, a Novel Analog of (1–3) IGF-1, as a Potential Therapeutic Agent for Fragile X Syndrome

@article{Deacon2015NNZ2566AN,
  title={NNZ-2566, a Novel Analog of (1–3) IGF-1, as a Potential Therapeutic Agent for Fragile X Syndrome},
  author={R. Deacon and L. Glass and M. Snape and M. J. Hurley and Francisco Altimiras and Rodolfo R. Biekofsky and P. Cogram},
  journal={NeuroMolecular Medicine},
  year={2015},
  volume={17},
  pages={71-82}
}
  • R. Deacon, L. Glass, +4 authors P. Cogram
  • Published 2015
  • Psychology, Medicine
  • NeuroMolecular Medicine
  • AbstractFragile X syndrome (FXS) is the most common form of inherited intellectual disability. Previous studies have implicated mGlu5 in the pathogenesis of the disease, and many agents that target the underlying pathophysiology of FXS have focused on mGluR5 modulation. In the present work, a novel pharmacological approach for FXS is investigated. NNZ-2566, a synthetic analog of a naturally occurring neurotrophic peptide derived from insulin-like growth factor-1 (IGF-1), was administered to… CONTINUE READING
    40 Citations
    Acamprosate in a mouse model of fragile X syndrome: modulation of spontaneous cortical activity, ERK1/2 activation, locomotor behavior, and anxiety
    • 17
    The Search for an Effective Therapy to Treat Fragile X Syndrome: Dream or Reality?
    • 16
    • PDF
    Changes in insulin‐like growth factor signaling alter phenotypes in Fragile X Mice
    • T. L. Wise
    • Biology, Medicine
    • Genes, brain, and behavior
    • 2017
    • 5
    Treating Rett syndrome: from mouse models to human therapies
    • 12
    • PDF
    The therapeutic potential of insulin-like growth factor-1 in central nervous system disorders
    • 35
    • Highly Influenced
    Fragile X targeted pharmacotherapy: lessons learned and future directions
    • 56

    References

    SHOWING 1-10 OF 42 REFERENCES
    AFQ056, a new mGluR5 antagonist for treatment of fragile X syndrome
    • 111
    Chronic Pharmacological mGlu5 Inhibition Corrects Fragile X in Adult Mice
    • 405
    Reversal of Disease-Related Pathologies in the Fragile X Mouse Model by Selective Activation of GABAB Receptors with Arbaclofen
    • 189
    NNZ-2566: A Gly–Pro–Glu analogue with neuroprotective efficacy in a rat model of acute focal stroke
    • 23
    IGF‐1 derived small neuropeptides and analogues: a novel strategy for the development of pharmaceuticals for neurological conditions
    • 41
    Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP
    • 483
    • PDF
    Dysregulation of mTOR Signaling in Fragile X Syndrome
    • 462
    • PDF
    Partial reversal of Rett Syndrome-like symptoms in MeCP2 mutant mice
    • 472
    • PDF
    A fragile balance: FMR1 expression levels.
    • 114
    • PDF
    Altered mTOR signaling and enhanced CYFIP2 expression levels in subjects with fragile X syndrome
    • 136
    • PDF